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INTRODUCTION
The proportion of older patients within the general population 
is gradually increasing, especially in advanced countries. Coro-
nary artery disease is the leading cause of death in the elderly, 
and chronic conditions associated with coronary artery disease 
are an important health issue.1 In daily clinical practice, medi-
cal treatment rather than percutaneous coronary intervention 
(PCI) is typically preferred in elderly patients due to a higher in-
cidence of multiple extra-cardiac comorbidities, fragile physical 
performance, and an increased risk of complications resulting 
from this invasive procedure in this population. Therefore, el-
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Purpose: Data comparing the clinical benefits of medical treatment with those of percutaneous coronary intervention (PCI) in an 
elderly population with angina pectoris are limited. Therefore, we evaluated the efficacy of elective PCI versus optimal medical 
treatment (OMT) in elderly patients (between 75 and 84 years old) with angina pectoris.
Materials and Methods: One hundred seventy-seven patients with significant coronary artery stenosis were randomly assigned to 
either the PCI group (n=90) or the OMT group (n=87). The primary outcome was a composite of major adverse events in the 1-year 
follow-up period that included cardiovascular death, non-fatal myocardial infarction, coronary revascularization, and stroke.
Results: Major adverse events occurred in 5 patients (5.6%) of the PCI group and in 17 patents (19.5%) of the OMT group (p=0.015). 
There were no significant differences between the PCI group and the OMT group in cardiac death [hazard ratio (HR) for the PCI 
group 0.454; 95% confidence interval (CI) 0.041–5.019, p=0.520], myocardial infarction (HR 0.399; 95% CI 0.039–4.050, p=0.437), or 
stroke (HR 0.919; 95% CI 0.057–14.709, p=0.952). However, the PCI group showed a significant preventive effect of the composite of 
major adverse events (HR 0.288; 95% CI 0.106–0.785, p=0.015) and against the need for coronary revascularization (HR 0.157; 95% CI 
0.035–0.703, p=0.016).
Conclusion: Elective PCI reduced major adverse events and was found to be an effective treatment modality in elderly patients 
with angina pectoris and significant coronary artery stenosis, compared to OMT.
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derly patients have mostly been excluded from study popula-
tions in randomized PCI trials. Nevertheless, data indicate that 
PCI is an effective treatment option for myocardial infarction in 
elderly patients.2,3 As the technical skills of those administering 
PCI advance along with the device technology itself, PCI-relat-
ed adverse cardiovascular events have progressively decreased 
over time in elderly patients.4-6 Indeed, a recent observational 
study reported that PCI reduced mortality in older patients with 
acute coronary syndrome.7 Furthermore, PCI may alleviate 
symptoms and improve the quality of life in elderly patients. 
However, there is limited data directly comparing the effects of 
PCI to that of medical treatment in elderly patients with angina 
pectoris. Therefore, the objective of this study was to compare 
clinical outcomes of elderly patients (≥75 years old) with angina 
pectoris who were treated with optimal medical treatment 
(OMT) to those who were treated with elective PCI with drug-
eluting stent implantation.
MATERIALS AND METHODS
This study was a prospective, multicenter, randomized clini-
cal trial conducted at six centers in Korea (ClinicalTrials.gov, 
NCT01508663). Inclusion criteria were patients between 75 and 
84 years of age; a clinical diagnosis of stable angina or unstable 
angina (Braunwald classification IB); and significant stenosis in 
at least one proximal epicardial coronary artery (diameter ste-
nosis of ≥70% by visual estimation). Exclusion criteria were a 
clinical diagnosis of unstable angina (Braunwald classification 
IIB or IIIB) or acute myocardial infarction; left ventricular ejec-
tion fraction less than 30%; history of prior PCI within 6 months; 
small vessel lesions not suitable for PCI; or a non-cardiac mor-
bidity with a life expectancy less than 2 years. This study was 
approved by the Institutional Review Board of each institute, 
and written informed consent was obtained from each patient.
Using an interactive web-based response system, patients 
were randomly assigned into either the PCI group or the OMT 
group. In the PCI group, patients were randomly assigned in a 
1:1 ratio to receive the Resolute zotarolimus-eluting stent (En-
deavor-Resolute stent, Medtronic vascular, Santa Rosa, CA, USA) 
or the everolimus-eluting stent (Xience, Abbott Vascular, Santa 
Clara, CA, USA). All patients in the PCI group received at least 
75 mg of aspirin and a loading dose of 300 mg of clopidogrel at 
least 12 hours pre-PCI. Unfractionated heparin was adminis-
tered to maintain the activated clotting time >250 seconds. All 
PCI procedures were performed according to current standard 
techniques. Post-procedure, dual antiplatelet therapy with as-
pirin (100 mg) and clopidogrel (75 mg) daily was prescribed for 
12 months. Procedural success was defined as the achievement 
of a final in-stent diameter stenosis of 30% or less by online 
quantitative coronary angiographic analysis or visual assess-
ment over the entire stent length, with normal coronary-artery 
flow. Medical treatment in both PCI and OMT groups included 
aspirin, statin, isosorbide nitrate, calcium-channel blocker, long-
acting beta-blocker, and angiotensin converting enzyme inhibi-
tor or angiotensin receptor blocker alone or in combination. All 
patients were scheduled to visit the clinic at 3, 6, 9, and 12 
months after coronary angiography. Revascularization was rec-
ommended when patients had recurrent or refractory angina 
symptom after discharge from treatment by randomization.
Data were collected from and documented in electronic clin-
ical research forms by dedicated research coordinators. The 
primary end point was the composite of cardiovascular death, 
stroke, non-fatal myocardial infarction, and coronary revascu-
larization for 1 year after the randomization. Clinical events 
were defined according to the Academic Research Consor-
tium.8 All deaths were considered cardiac deaths unless a defi-
nite non-cardiac cause was established. Myocardial infarction 
was defined as the presence of clinical symptoms, electrocar-
diographic changes, or abnormal imaging findings of myocar-
dial infarction, combined with an increase in the creatine ki-
nase myocardial band fraction above the upper normal limits 
or an increase in troponin-T/troponin-I to greater than the 99th 
percentile of the upper normal limit. Clinical assessment was 
performed during a scheduled visit to an outpatient clinic.
In the PCI group, quantitative coronary angiographic analysis 
was performed using an off-line quantitative coronary angio-
graphic system (CASS system, Pie Medical Instruments, Maas-
tricht, the Netherlands), before and after stent implantation, by 
analysts in an independent core laboratory at the Cardiovascu-
lar Research Center, Seoul, Korea. Using the guiding catheter 
for magnification-calibration, the diameters of the reference 
vessel and the minimal luminal diameter were measured be-
fore and after stenting from diastolic frames in a single matched 
view showing the smallest minimal luminal diameter.
The sample size was calculated using a two-sample inequality 
test. Based on previous data showing the composite of cardio-
vascular death, stroke, nonfatal myocardial infarction, or coro-
nary revascularization occurred in 23.5% of the PCI-treated 
group and in 30.0% of the OMT-treated group,9,10 we assumed 
that PCI would reduce the composite events by 6.5% compared 
to the OMT group in our study. Assuming a two-sided alpha lev-
el of 0.05, statistical power of 80%, and estimated dropout rate of 
10%, we calculated 800 hundred patients were needed for each 
arm.
For comparing categorical variables we conducted the χ2 test 
or Fisher’s exact test. To compare continuous variables the Stu-
dent t-test was conducted. Cumulative incidences of composite 
events at 12 months (the primary outcomes) were calculated us-
ing Kaplan-Meier estimates. Comparison between the two 
groups was performed using the log-rank test. Univariate and 
multivariate logistic regression models were applied to deter-
mine risk factors for the composite events. Statistical analysis was 
performed using the SPSS software (version 18.0.0; SPSS Inc., Chi-
cago, IL, USA). A value of p<0.05 was considered statistically sig-
nificant.
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RESULTS
Patients were enrolled between December 2010 and June 2012. 
The recruitment process was prematurely terminated due to dif-
ficulty in enrolling patients due to physician or patient prefer-
ence. During the study period, 182 patients were included in 
this study. A total of 5 patients were excluded. Three patients 
withdrew informed consent, and 2 patients violated study pro-
tocol. Of the remaining 177 patients, 87 OMT group patients 
and 90 PCI group patients (zotarolimus-eluting stent in 46 pa-
tients and everolimus-eluting stent in 44 patients) were includ-
ed in the final analysis. Baseline clinical characteristics were 
similar between the two groups (Table 1). Lesion and procedur-
al characteristics of the PCI group are listed in Table 2. The tran-
sradial approach was performed at a similar rate between two 
groups (58.9% in PCI and 60.9% in OMT, p=0.783). All PCI pro-
cedures were successfully performed without complications.
One year clinical outcomes between of both groups are shown 
in Table 3. Although cardiac mortality, myocardial infarction, 
and stroke were not statistically different between the two groups, 
coronary revascularization was significantly greater in the OMT 
group than in the PCI group (13.8% vs. 2.2%, respectively, 
p=0.016). The composite of adverse events during the one-year 
follow-up period occurred in five patients (5.6%) in the PCI group 
and in 17 patients (19.5%) in OMT group (log rank p=0.010) (Fig. 
1). The improved outcome primarily resulted from the differ-
ence of coronary revascularization due to recurrent angina in 
elderly patients.
Of these patients in the PCI group, major adverse events in-
cluded one stroke in a patient with a zotarolimus-eluting, one 
cardiac death, one myocardial infarction, and two target-lesion 
revascularization procedures were conducted in everolimus-
eluting stent-treated patients (p=0.152). By multivariate Cox re-
gression analysis, PCI was an independent predictor for the 
composite of adverse events (hazard ratio=0.285, 95% confi-
dence interval 0.102–0.796, p=0.017) (Table 4).
Table 1. Baseline Clinical Characteristics
PCI group (n=90) OMT group (n=87) p value
Age 78.0±4.2 78.3±4.7 0.666
Male 46 (51.1) 42 (48.3) 0.764
Diabetes mellitus 36 (40.0) 28 (32.2) 0.348
Hypertension 74 (82.2) 65 (74.7) 0.273
Dyslipidemia 39 (43.3) 39 (44.8) 0.880
Smoking 18 (20.0) 14 (16.1) 0.787
Chronic kidney disease 2 (2.2) 0 (0.0) 0.497
LVEF <45% 5 (5.6) 5 (5.7) 0.999
Previous myocardial infarction 6 (6.7) 4 (4.6) 0.747
Initial diagnosis 0.529
Stable angina 56 (62.2) 59 (67.8)
Unstable angina 34 (37.8) 28 (32.2)
Multi-vessel disease 44 (50.6) 45 (57.0) 0.536
Laboratory
Hemoglobin 12.3±1.8 12.6±1.6 0.430
Creatinine 1.1±0.7 1.0±0.4 0.542
Total cholesterol 154.0 (94.0–252.0) 163.5 (84.0–302.0) 0.063
Triglyceride 104.0 (22.0–777.0) 111.5 (47.0–422.0) 0.171
HDL cholesterol 42.0 (27.0–68.0) 40.0 (17.0–81.0) 0.728
LDL cholesterol 88.0 (37.0–161.0) 100.0 (24.0–197.0) 0.157
Medication at discharge
Aspirin 90 (100.0) 86 (98.9) 0.492
ACEi or ARB 64 (71.1) 60 (69.0) 0.870
Beta blockers 62 (68.9) 57 (65.5) 0.749
Calcium channel blockers 40 (44.4) 48 (55.2) 0.177
Isosorbide nitrate 47 (52.2) 59 (67.8) 0.046
Statin 88 (98.9) 85 (97.7) 0.619
PCI, percutaneous coronary intervention; OMT, optimal medical treatment; LVEF, left ventricular ejection fraction; HDL, high-density lipoprotein; LDL, low-density 
lipoprotein; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.
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DISCUSSION
This prospective randomized study showed that, compared to 
OMT, PCI reduces major adverse outcomes in elderly patients 
≥75 years of age.
The Trial of Invasive versus Medical Therapy in Elderly Pa-
tients with Chronic Symptomatic Coronary Artery Disease 
(TIME) trial was the first randomized controlled trial to com-
pare invasive revascularization including PCI and coronary ar-
tery bypass surgery with OMT in elderly patients (≥75 years) 
Table 2. Angiographic & Procedural Characteristics in PCI Group
Treated number of lesions n=104
Location of lesion
Left main artery 3 (2.9)
Left anterior descending artery 49 (47.1)
Left circumflex artery 20 (19.2)
Right coronary artery 32 (30.8)
Type of lesion, B2/C 75 (72.1)
Bifurcation lesion 7 (6.4)
Baseline
Reference vessel diameter, mm 2.8±0.5
Minimal lumen diameter, mm 1.0±0.6
% diameter stenosis 65.5±18.1
Post-PCI
Reference vessel diameter, mm 2.9±0.4
Minimal lumen diameter, mm 2.6±0.5
% diameter stenosis 9.3±8.9
Stent length, mm 21.7±7.3
Stent size, mm 2.9±0.4
Maximal inflation pressure 16.2±2.4
PCI, percutaneous coronary intervention.
Table 3. Clinical Outcomes through 1 Year
PCI group (n=90) OMT group (n=87) Hazard ratio (95% CI) p value
Death 
All cause 6 (6.7) 4 (4.6) 1.003 (0.267–3.767) 0.997
Cardiovascular cause 1 (1.1) 2 (2.3) 0.454 (0.041–5.019) 0.520
Myocardial infarction 1 (1.1) 3 (3.4) 0.399 (0.039–4.050) 0.437
Stroke 1 (1.1) 1 (1.1) 0.919 (0.057–14.709) 0.952
Coronary revascularization 2 (2.2) 12 (13.8) 0.157 (0.035–0.703) 0.016
Stent thrombosis 0 (0.0) -
Composite of cardiac death, myocardial infarction, 
   stroke or coronary revascularization
5 (5.6) 17 (19.5) 0.288 (0.106–0.785) 0.015
PCI, percutaneous coronary intervention; OMT, optimal medical treatment; CI, confidence interval.
Table 4. Univariate and Multivariate Cox Regression Analysis for Prediction of Major Adverse Cardiac Events
Variable
Univariate Multivariate
Hazard ratio 95% confidence interval p value Hazard ratio 95% confidence interval p value
Age 1.061 0.943–1.193 0.328 1.099 0.964–1.254 0.158
Male 0.681 0.291–1.596 0.377 0.661 0.252–1.737 0.401
Hypertension 2.774 0.646–11.916 0.170 1.968 0.567–6.823 0.286
Diabetes mellitus 2.136 0.904–5.045 0.084 1.838 0.732–4.616 0.195
Smoking history 0.484 0.113–2.078 0.329 0.673 0.140–3.229 0.620
Multivessel disease 1.654 0.658–4.154 0.284 1.887 0.730–4.877 0.190
Unstable angina 0.716 0.280–1.832 0.486 0.873 0.325–2.342 0.787
Percutaneous coronary intervention 0.288 0.106–0.785 0.015 0.285 0.102–0.796 0.017
Fig. 1. Rate of composite adverse events for the 1 year follow-up duration. 
OMT, optimal medical treatment; PCI, percutaneous coronary interven-
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with stable angina. In that study, invasive revascularization re-
duced adverse cardiovascular events, an effect mainly due to 
reduced re-hospitalization with medically uncontrolled angina 
symptoms during the 6 months of follow-up.11 However, it is 
important to note that differences in symptom control and qual-
ity of life improvement between the two study groups were not 
observed within 1 year of follow-up.12 Furthermore, after 4 years 
of follow-up, the long term survival rate was similar between 
the invasive and medically treated groups.13 However, symptom 
relief and improved quality of life in the invasive treatment 
group, compared to the medical treatment group, was main-
tained over the duration of the 4-year follow-up period.13 In the 
TIME trial, coronary revascularization, including both PCI and 
coronary bypass graft surgery, was compared with medical 
therapy. This made it difficult to evaluate the effect of PCI alone 
on long-term clinical outcomes. Furthermore, PCI was per-
formed with a bare-metal stent. With evolving PCI technologies 
and techniques, as well as adjunctive medical therapy, adverse 
cardiovascular events after PCI have significantly decreased 
over time in elderly patients.4-6 In the current study, PCI using 
second-generation drug-eluting stents was directly compared 
with medical therapy in elderly patients.
The importance of statin therapy for the treatment and pre-
vention of coronary artery disease has been increasingly em-
phasized over the last decade. In the TIME trial, about 20% of 
patients were on statin treatment, while in our study, almost all 
patients took a statin. In the TIME trial, major adverse cardio-
vascular events during the 1-year follow-up occurred in 25.5% 
of the invasive revascularization group and in 64.2% of the 
medical treatment group; all-cause mortality was 11.1% and 
8.1%, respectively.12 In the present study, the rate of major ad-
verse cardiovascular events was significantly lower. Advances 
in PCI techniques, accumulated technical experience, and ad-
vances in devices, as well as medical therapy, likely improved 
the clinical outcomes for elderly patients in both the PCI and 
OMT groups included in our study.
Over the past decade, the average life expectancy in Korea 
has increased about 5 years, and is now greater than 75 years.14 
Furthermore, a reduced rate of disability in older Koreans has 
led to a substantially improved functional status of this popula-
tion.15 Similar trends of prolonged survival and declined disabil-
ity are observed in developed countries.16-18 Despite improved 
physical functioning in elderly population, the prevalences of 
chronic diseases like ischemic heart disease have contin-
ued.14,19 In elderly patients with angina pectoris, relieving an-
gina symptoms may lead a higher quality of life over the in-
creased life expectancy. Treating angina pectoris in elderly 
patients with medical treatment alone may increase in the 
suffering and psychological distress related to the condition. 
A recent study reported that the quality of life and symptom 
relief in octogenarian patients with coronary artery disease fol-
lowing PCI improved to a level similar to that observed in 
younger patients.20 In terms of cost-effectiveness, one study re-
ported that invasive treatment had a similar benefit to medical 
management in elderly patients with chronic angina symp-
toms.21 However, within clinical practice, PCI is underused in 
older patients (≥75 years old) with acute coronary syndrome, 
especially in those with more complex risk factors.7
Advanced age is an independent risk factor for mortality and 
morbidity in PCI.4,22 This safety issue is an important factor 
when considering PCI in elderly patients. The higher prevalence 
of diffuse disease, severe calcification, and tortuosity in the el-
derly may explain the high risk of complications and procedur-
al failure in this population. Over the last 10 years, therapeutic 
developments have improved clinical outcomes following 
PCI.4-6,23 Increased frequency of the transradial approach has 
reduced vascular complications and major bleeding.24,25 Elderly 
patients have a significantly higher risk of arterial access com-
plications. Therefore, a lower incidence of vascular complica-
tions may be particularly beneficial in this patient population.26 
In the present study, transradial PCI was performed in about 
60% of patients without any resulting complications. Moreover, 
a recent study from the SHINANO registry, in which 63.2% of 
the procedures were transradial, reported that the procedure 
success rate and in-hospital major adverse cardiovascular out-
comes in an octogenarian cohort were similar to those ob-
served in younger patients who underwent elective PCI.27 Simi-
larly, elective PCI in elderly patients had favorable clinical 
outcomes in a study from the New York State Angioplasty Reg-
istry.22 In the present study, PCI had favorable outcomes and 
did not increase procedure-related or bleeding complications.
The present study has limitations. First, statistical power was 
reduced because of the small number of patients enrolled in 
this study. Second, the results of this study may not be applica-
ble to patients with myocardial infarction or asymptomatic pa-
tients. Third, the decision of revascularization in re-admitted 
patients was at the discretion of physicians, although we rec-
ommended revascularization in patients with recurrent angina. 
Furthermore, we have not assessed quality of life, but most recur-
rently symptomatic patients were treated by revascularization.
In summary, PCI improved chest symptoms and reduced re-
admission related to recurrent angina, compared to optimal 
medical treated elderly patients; meanwhile, no reductions in 
mortality and myocardial infarction were noted. These data in-
dicate that PCI is effective and feasible in symptomatic elderly 
patients with angina pectoris. Chronological age alone should 
not be considered as a contraindication for PCI, and PCI should 
be considered as a primary treatment strategy in this patient 
population.
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